199 related articles for article (PubMed ID: 28248808)
21. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
[TBL] [Abstract][Full Text] [Related]
22. [Response to milrinone treatment in patients with chronic congestive heart failure].
Zeng H; Wen S; Huang D; Liu X; Fang Y
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun; 31(2):246-7, 259. PubMed ID: 12515150
[TBL] [Abstract][Full Text] [Related]
23. Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Apostolopoulou SC; Vagenakis GA; Tsoutsinos A; Kakava F; Rammos S
Pediatr Cardiol; 2018 Oct; 39(7):1315-1322. PubMed ID: 29777282
[TBL] [Abstract][Full Text] [Related]
24. Long-term support with milrinone prior to cardiac transplantation in a neonate with left ventricular noncompaction cardiomyopathy.
McMahon CJ; Murchan H; Prendiville T; Burch M
Pediatr Cardiol; 2007; 28(4):317-8. PubMed ID: 17551772
[TBL] [Abstract][Full Text] [Related]
25. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
Varriale P; Ramaprasad S
Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
[TBL] [Abstract][Full Text] [Related]
26. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Cuffe MS; Califf RM; Adams KF; Benza R; Bourge R; Colucci WS; Massie BM; O'Connor CM; Pina I; Quigg R; Silver MA; Gheorghiade M;
JAMA; 2002 Mar; 287(12):1541-7. PubMed ID: 11911756
[TBL] [Abstract][Full Text] [Related]
27. [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone].
Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):599-602. PubMed ID: 8697925
[TBL] [Abstract][Full Text] [Related]
28. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure.
Hatzizacharias A; Makris T; Krespi P; Triposkiadis F; Voyatzi P; Dalianis N; Kyriakidis M
Am Heart J; 1999 Aug; 138(2 Pt 1):241-6. PubMed ID: 10426834
[TBL] [Abstract][Full Text] [Related]
29. Canadian Palliative Community Milrinone Infusions: A Case Series.
Reimche R; Salcedo D
Can J Cardiovasc Nurs; 2016; 26(1):9-13. PubMed ID: 27159935
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
31. Intravenous home inotropic use is safe in pediatric patients awaiting transplantation.
Birnbaum BF; Simpson KE; Boschert TA; Zheng J; Wallendorf MJ; Schechtman K; Canter CE
Circ Heart Fail; 2015 Jan; 8(1):64-70. PubMed ID: 25472966
[TBL] [Abstract][Full Text] [Related]
32. Randomized comparative study of intravenous infusion of three different fixed doses of milrinone in pediatric patients with pulmonary hypertension undergoing open heart surgery.
Barnwal NK; Umbarkar SR; Sarkar MS; Dias RJ
Ann Card Anaesth; 2017; 20(3):318-322. PubMed ID: 28701597
[TBL] [Abstract][Full Text] [Related]
33. Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Ryerson LM; Alexander PM; Butt WW; Shann FA; Penny DJ; Shekerdemian LS
Pediatr Crit Care Med; 2011 Jan; 12(1):57-60. PubMed ID: 20453705
[TBL] [Abstract][Full Text] [Related]
34. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
Bayram M; De Luca L; Massie MB; Gheorghiade M
Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
[TBL] [Abstract][Full Text] [Related]
35. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy.
Bhat G
ASAIO J; 2006; 52(6):677-81. PubMed ID: 17117058
[TBL] [Abstract][Full Text] [Related]
36. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
Felker GM; Benza RL; Chandler AB; Leimberger JD; Cuffe MS; Califf RM; Gheorghiade M; O'Connor CM;
J Am Coll Cardiol; 2003 Mar; 41(6):997-1003. PubMed ID: 12651048
[TBL] [Abstract][Full Text] [Related]
37. IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Heinz G; Geppert A; Delle Karth G; Reinelt P; Gschwandtner ME; Neunteufl T; Zauner C; Frossard M; Siostrzonek P
Intensive Care Med; 1999 Jun; 25(6):620-4. PubMed ID: 10416916
[TBL] [Abstract][Full Text] [Related]
38. Long-term milrinone therapy in children with dilated cardiomyopathy.
Brown S; Nolan O; Poole E; Kidd J; Cassidy J; Botha P; Chaudhari M
Acta Paediatr; 2023 Jun; 112(6):1298-1303. PubMed ID: 36867057
[TBL] [Abstract][Full Text] [Related]
39. Intravenous milrinone in treatment of advanced congestive heart failure.
Zewail AM; Nawar M; Vrtovec B; Eastwood C; Kar MN; Delgado RM
Tex Heart Inst J; 2003; 30(2):109-13. PubMed ID: 12809251
[TBL] [Abstract][Full Text] [Related]
40. [Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure].
Brügemann J; de Jonge-Weber AT; Rienstra M; van den Broek SA; Zijlstra F; van Veldhuisen DJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2460-5. PubMed ID: 18064867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
